Clinical Trial Update: Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

View source ↗

Summary

Expanded access program for abemaciclib (Verzenio) for metastatic breast cancer has been approved for marketing. This enables broader patient access outside tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Status: APPROVED_FOR_MARKETING